Etigilimab clinical trials
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2017
How each study uses etigilimab has had a first review. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
3 studies that test it; most in 2021 (2)
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2021 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 2 · Other 1
M.D. Anderson Cancer Center (1) · Mereo BioPharma (1) · OncoMed Pharmaceuticals, Inc. (1)
Related medicines
As reviewed, each with the page that says it.
Studies
Open first, then newest update. How each study uses etigilimab has had a first review, but it may not be perfect: check the study record before relying on it for anything important, and report a problem from its row. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- EON: A Single-arm Phase II Study of Etigilimab (OMP-313M32) in Combination With Checkpoint Inhibition (Nivolumab) in Patients With Platinum-resistant, Recurrent Epithelial Ovarian CancerActive, not recruitingPhase 2M.D. Anderson Cancer CenterNCT05715216Written as EtigilimabHow we knowReport a problem
- A Study of Etigilimab and Nivolumab in Participants With Locally Advanced or Metastatic TumorsCompletedPhase 1/2Mereo BioPharmaNCT04761198Written as EtigilimabHow we knowReport a problem
- A Study of OMP-313M32 in Subjects With Locally Advanced or Metastatic Solid TumorsTerminatedPhase 1OncoMed Pharmaceuticals, Inc.NCT03119428Written as OMP-313M32How we knowReport a problem
Tested with established drugs · 3 — they are given beside it
- EON: A Single-arm Phase II Study of Etigilimab (OMP-313M32) in Combination With Checkpoint Inhibition (Nivolumab) in Patients With Platinum-resistant, Recurrent Epithelial Ovarian CancerActive, not recruitingPhase 2M.D. Anderson Cancer CenterNCT05715216Written as EtigilimabHow we knowReport a problem
- A Study of Etigilimab and Nivolumab in Participants With Locally Advanced or Metastatic TumorsCompletedPhase 1/2Mereo BioPharmaNCT04761198Written as EtigilimabHow we knowReport a problem
- A Study of OMP-313M32 in Subjects With Locally Advanced or Metastatic Solid TumorsTerminatedPhase 1OncoMed Pharmaceuticals, Inc.NCT03119428Written as OMP-313M32How we knowReport a problem
Codes
What other systems call etigilimab · ClinicalTrials.gg INT016550
- UNII (FDA) FC1ZF28VITETIGILIMABOne source FDA
- NCI Thesaurus C142821EtigilimabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | FC1ZF28VIT | ETIGILIMAB | One source FDA |
| NCI Thesaurus | C142821 | Etigilimab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.